| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Heart Failure | 12 | 2016 | 1422 | 1.760 |
Why?
|
| Stroke Volume | 6 | 2016 | 531 | 1.270 |
Why?
|
| Myocardial Infarction | 7 | 2009 | 429 | 1.060 |
Why?
|
| Antihypertensive Agents | 6 | 2011 | 264 | 1.020 |
Why?
|
| Anti-Arrhythmia Agents | 5 | 2012 | 69 | 0.940 |
Why?
|
| Adrenergic beta-Antagonists | 4 | 2012 | 110 | 0.890 |
Why?
|
| Hypertension | 6 | 2011 | 774 | 0.790 |
Why?
|
| Aspirin | 3 | 2008 | 169 | 0.780 |
Why?
|
| Angioplasty, Balloon, Coronary | 5 | 2009 | 67 | 0.770 |
Why?
|
| Acute Coronary Syndrome | 3 | 2013 | 34 | 0.740 |
Why?
|
| Hospitalization | 5 | 2016 | 943 | 0.710 |
Why?
|
| Heart Rate | 3 | 2012 | 518 | 0.590 |
Why?
|
| Ticlopidine | 2 | 2009 | 26 | 0.580 |
Why?
|
| Quality of Health Care | 3 | 2011 | 403 | 0.570 |
Why?
|
| Long QT Syndrome | 2 | 2008 | 39 | 0.560 |
Why?
|
| Humans | 66 | 2016 | 95800 | 0.560 |
Why?
|
| Postprandial Period | 2 | 2008 | 48 | 0.550 |
Why?
|
| Potassium | 2 | 2009 | 271 | 0.540 |
Why?
|
| Hospital Mortality | 3 | 2016 | 483 | 0.530 |
Why?
|
| Anticoagulants | 2 | 2013 | 463 | 0.520 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2009 | 180 | 0.510 |
Why?
|
| Hyperglycemia | 2 | 2008 | 181 | 0.500 |
Why?
|
| Coronary Vessels | 2 | 2009 | 201 | 0.490 |
Why?
|
| Heart | 2 | 2009 | 590 | 0.480 |
Why?
|
| Coronary Artery Disease | 4 | 2011 | 394 | 0.470 |
Why?
|
| Stents | 2 | 2009 | 422 | 0.470 |
Why?
|
| Secondary Prevention | 3 | 2013 | 179 | 0.460 |
Why?
|
| Length of Stay | 2 | 2016 | 833 | 0.430 |
Why?
|
| Arrhythmias, Cardiac | 3 | 2016 | 206 | 0.420 |
Why?
|
| Sepsis | 2 | 2008 | 389 | 0.410 |
Why?
|
| Cardiovascular Diseases | 3 | 2009 | 777 | 0.400 |
Why?
|
| Atrial Fibrillation | 2 | 2008 | 392 | 0.390 |
Why?
|
| Amiodarone | 2 | 2008 | 15 | 0.350 |
Why?
|
| Medically Uninsured | 1 | 2011 | 67 | 0.340 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2011 | 61 | 0.340 |
Why?
|
| Ventricular Function, Left | 3 | 2010 | 662 | 0.340 |
Why?
|
| Tachycardia | 2 | 2012 | 36 | 0.340 |
Why?
|
| Vasopressins | 2 | 2001 | 50 | 0.330 |
Why?
|
| Oxytocin | 2 | 2001 | 75 | 0.320 |
Why?
|
| Coronary Disease | 2 | 2008 | 263 | 0.310 |
Why?
|
| Carotid Sinus | 1 | 2009 | 20 | 0.310 |
Why?
|
| Heart Failure, Systolic | 1 | 2009 | 6 | 0.310 |
Why?
|
| Ventricular Dysfunction, Left | 2 | 2010 | 340 | 0.310 |
Why?
|
| Pericardial Effusion | 1 | 2009 | 23 | 0.310 |
Why?
|
| Atenolol | 1 | 2009 | 26 | 0.310 |
Why?
|
| Blood Pressure | 5 | 2011 | 926 | 0.310 |
Why?
|
| Syncope | 1 | 2009 | 37 | 0.300 |
Why?
|
| Aged | 17 | 2016 | 20848 | 0.300 |
Why?
|
| Stroke | 6 | 2011 | 1087 | 0.300 |
Why?
|
| Electrocardiography | 2 | 2009 | 522 | 0.300 |
Why?
|
| Coronary Artery Bypass | 2 | 2008 | 252 | 0.300 |
Why?
|
| Proton Pump Inhibitors | 1 | 2009 | 34 | 0.300 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 59 | 0.290 |
Why?
|
| Myocarditis | 1 | 2009 | 58 | 0.290 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2008 | 40 | 0.290 |
Why?
|
| Protease Inhibitors | 1 | 2009 | 72 | 0.290 |
Why?
|
| Aortic Aneurysm, Abdominal | 1 | 2010 | 121 | 0.290 |
Why?
|
| Naproxen | 1 | 2008 | 15 | 0.290 |
Why?
|
| Cause of Death | 1 | 2010 | 278 | 0.290 |
Why?
|
| Prostaglandins | 1 | 2008 | 44 | 0.290 |
Why?
|
| Prognosis | 8 | 2012 | 3990 | 0.290 |
Why?
|
| Propanolamines | 1 | 2008 | 18 | 0.280 |
Why?
|
| Hypoglycemia | 1 | 2009 | 112 | 0.280 |
Why?
|
| Ganglionectomy | 1 | 2008 | 2 | 0.280 |
Why?
|
| Syncope, Vasovagal | 1 | 2008 | 6 | 0.280 |
Why?
|
| Propranolol | 1 | 2008 | 44 | 0.280 |
Why?
|
| Fingers | 1 | 2008 | 69 | 0.280 |
Why?
|
| Myoglobin | 1 | 2008 | 29 | 0.280 |
Why?
|
| Endarterectomy, Carotid | 1 | 2008 | 76 | 0.280 |
Why?
|
| Platelet Glycoprotein GPIIb-IIIa Complex | 1 | 2008 | 11 | 0.280 |
Why?
|
| Atherosclerosis | 2 | 2008 | 267 | 0.280 |
Why?
|
| Creatine Kinase | 1 | 2008 | 53 | 0.280 |
Why?
|
| Inpatients | 1 | 2011 | 347 | 0.280 |
Why?
|
| Troponin I | 1 | 2008 | 27 | 0.270 |
Why?
|
| Clostridium perfringens | 1 | 2007 | 8 | 0.270 |
Why?
|
| Vascular Malformations | 1 | 2008 | 19 | 0.270 |
Why?
|
| Umbilicus | 1 | 2007 | 3 | 0.270 |
Why?
|
| Medicare | 1 | 2011 | 458 | 0.270 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 1 | 2008 | 46 | 0.270 |
Why?
|
| Atrioventricular Node | 1 | 2008 | 36 | 0.270 |
Why?
|
| Aged, 80 and over | 8 | 2016 | 7215 | 0.270 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2007 | 10 | 0.270 |
Why?
|
| Thiazolidinediones | 1 | 2008 | 76 | 0.270 |
Why?
|
| Radiation Injuries | 1 | 2009 | 159 | 0.270 |
Why?
|
| Dopamine Uptake Inhibitors | 1 | 2008 | 44 | 0.270 |
Why?
|
| Coronary Vasospasm | 1 | 2007 | 8 | 0.270 |
Why?
|
| Hypertriglyceridemia | 1 | 2008 | 72 | 0.270 |
Why?
|
| Carotid Stenosis | 1 | 2008 | 115 | 0.270 |
Why?
|
| Dyslipidemias | 1 | 2009 | 109 | 0.270 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2008 | 98 | 0.270 |
Why?
|
| Natriuretic Agents | 1 | 2007 | 2 | 0.270 |
Why?
|
| Hyperlipidemias | 1 | 2008 | 91 | 0.270 |
Why?
|
| Echocardiography | 2 | 2010 | 1004 | 0.270 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2010 | 239 | 0.260 |
Why?
|
| Aortic Valve Stenosis | 1 | 2009 | 166 | 0.260 |
Why?
|
| Cocaine | 1 | 2008 | 81 | 0.260 |
Why?
|
| Risk Assessment | 6 | 2010 | 2480 | 0.260 |
Why?
|
| Defibrillators, Implantable | 1 | 2009 | 156 | 0.260 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2007 | 60 | 0.260 |
Why?
|
| Female | 24 | 2016 | 49872 | 0.260 |
Why?
|
| Transforming Growth Factor beta | 1 | 2009 | 349 | 0.260 |
Why?
|
| Pulmonary Veins | 1 | 2008 | 96 | 0.260 |
Why?
|
| Clostridium Infections | 2 | 2014 | 128 | 0.260 |
Why?
|
| Ischemia | 1 | 2008 | 256 | 0.250 |
Why?
|
| Bretylium Compounds | 1 | 2006 | 1 | 0.250 |
Why?
|
| Male | 23 | 2016 | 45686 | 0.250 |
Why?
|
| Clindamycin | 1 | 2006 | 15 | 0.250 |
Why?
|
| Diuretics | 1 | 2007 | 77 | 0.250 |
Why?
|
| Mitral Valve | 1 | 2009 | 279 | 0.250 |
Why?
|
| Skin Diseases, Vesiculobullous | 1 | 2006 | 18 | 0.250 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2008 | 249 | 0.250 |
Why?
|
| Mitral Valve Insufficiency | 1 | 2009 | 209 | 0.250 |
Why?
|
| Critical Illness | 1 | 2009 | 346 | 0.250 |
Why?
|
| Drug Therapy, Combination | 4 | 2009 | 787 | 0.240 |
Why?
|
| Cardiotonic Agents | 1 | 2007 | 95 | 0.240 |
Why?
|
| Vasodilator Agents | 1 | 2007 | 151 | 0.240 |
Why?
|
| Ventricular Fibrillation | 1 | 2006 | 70 | 0.240 |
Why?
|
| Drug Eruptions | 1 | 2006 | 35 | 0.240 |
Why?
|
| Body Mass Index | 1 | 2010 | 815 | 0.240 |
Why?
|
| Geriatric Assessment | 1 | 2007 | 192 | 0.240 |
Why?
|
| Prenatal Diagnosis | 1 | 2006 | 110 | 0.240 |
Why?
|
| Referral and Consultation | 1 | 2009 | 386 | 0.240 |
Why?
|
| Critical Care | 1 | 2009 | 447 | 0.230 |
Why?
|
| Adenosine Triphosphate | 3 | 2001 | 329 | 0.230 |
Why?
|
| Patient Selection | 1 | 2009 | 708 | 0.230 |
Why?
|
| Thrombolytic Therapy | 1 | 2008 | 261 | 0.230 |
Why?
|
| Blood Glucose | 1 | 2009 | 873 | 0.230 |
Why?
|
| Melanoma | 1 | 2009 | 495 | 0.230 |
Why?
|
| Hypoglycemic Agents | 1 | 2008 | 376 | 0.220 |
Why?
|
| Supraoptic Nucleus | 2 | 2001 | 2 | 0.220 |
Why?
|
| Stomach Neoplasms | 1 | 2007 | 310 | 0.210 |
Why?
|
| Diabetes Mellitus | 1 | 2011 | 771 | 0.210 |
Why?
|
| Neuropeptide Y | 2 | 2001 | 31 | 0.210 |
Why?
|
| Hypertension, Pulmonary | 1 | 2008 | 381 | 0.210 |
Why?
|
| Substance P | 2 | 2001 | 62 | 0.210 |
Why?
|
| Middle Aged | 16 | 2016 | 28208 | 0.210 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2006 | 235 | 0.210 |
Why?
|
| Hypothalamo-Hypophyseal System | 2 | 2001 | 81 | 0.200 |
Why?
|
| Heart Arrest | 1 | 2007 | 312 | 0.200 |
Why?
|
| Pregnancy Complications | 1 | 2006 | 355 | 0.200 |
Why?
|
| Psoriasis | 1 | 2006 | 254 | 0.200 |
Why?
|
| Epidermal Cyst | 1 | 2003 | 7 | 0.200 |
Why?
|
| Meningitis, Aseptic | 1 | 2003 | 8 | 0.200 |
Why?
|
| Cardiac Surgical Procedures | 1 | 2008 | 514 | 0.200 |
Why?
|
| Obesity | 1 | 2010 | 1030 | 0.190 |
Why?
|
| Pituitary Gland, Posterior | 1 | 2001 | 3 | 0.180 |
Why?
|
| Spinal Neoplasms | 1 | 2003 | 131 | 0.180 |
Why?
|
| Randomized Controlled Trials as Topic | 4 | 2010 | 933 | 0.180 |
Why?
|
| Decision Making | 1 | 2007 | 694 | 0.180 |
Why?
|
| Diagnosis, Differential | 5 | 2014 | 1615 | 0.180 |
Why?
|
| Risk Factors | 8 | 2015 | 5961 | 0.170 |
Why?
|
| Hydrocortisone | 1 | 2003 | 299 | 0.170 |
Why?
|
| Neuropeptides | 1 | 2001 | 116 | 0.170 |
Why?
|
| Purinergic Agonists | 1 | 2000 | 1 | 0.170 |
Why?
|
| Adrenergic Agonists | 1 | 2000 | 2 | 0.170 |
Why?
|
| Pyridoxal Phosphate | 1 | 2000 | 12 | 0.170 |
Why?
|
| Neurotransmitter Agents | 1 | 2001 | 111 | 0.170 |
Why?
|
| Incidence | 3 | 2011 | 1714 | 0.170 |
Why?
|
| Anti-Bacterial Agents | 1 | 2006 | 847 | 0.160 |
Why?
|
| Adenocarcinoma | 1 | 2007 | 1192 | 0.160 |
Why?
|
| Survival Rate | 3 | 2009 | 1971 | 0.160 |
Why?
|
| HIV Infections | 1 | 2009 | 974 | 0.150 |
Why?
|
| Confidence Intervals | 2 | 2010 | 220 | 0.150 |
Why?
|
| Brain Ischemia | 2 | 2015 | 416 | 0.150 |
Why?
|
| Risk | 3 | 2010 | 665 | 0.140 |
Why?
|
| Treatment Outcome | 5 | 2011 | 9167 | 0.140 |
Why?
|
| Drug Interactions | 2 | 2009 | 245 | 0.140 |
Why?
|
| Contraindications | 2 | 2009 | 70 | 0.140 |
Why?
|
| Severity of Illness Index | 3 | 2010 | 1981 | 0.140 |
Why?
|
| Fatal Outcome | 2 | 2009 | 303 | 0.140 |
Why?
|
| Systole | 2 | 2008 | 116 | 0.140 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2010 | 883 | 0.130 |
Why?
|
| Survival Analysis | 3 | 2010 | 1540 | 0.130 |
Why?
|
| Phenylephrine | 3 | 2001 | 36 | 0.130 |
Why?
|
| Postoperative Complications | 1 | 2008 | 2592 | 0.130 |
Why?
|
| Reference Values | 2 | 2008 | 674 | 0.130 |
Why?
|
| Precipitating Factors | 1 | 2016 | 5 | 0.120 |
Why?
|
| Norepinephrine | 3 | 2001 | 173 | 0.120 |
Why?
|
| Ultrasonography | 2 | 2009 | 747 | 0.120 |
Why?
|
| Adult | 7 | 2009 | 28578 | 0.120 |
Why?
|
| Diarrhea | 2 | 2014 | 181 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2008 | 3639 | 0.120 |
Why?
|
| Weight Gain | 1 | 2016 | 129 | 0.120 |
Why?
|
| Brain Infarction | 1 | 2015 | 24 | 0.110 |
Why?
|
| Pellagra | 1 | 2014 | 2 | 0.110 |
Why?
|
| Delayed Diagnosis | 1 | 2014 | 41 | 0.110 |
Why?
|
| Dermatitis | 1 | 2014 | 35 | 0.110 |
Why?
|
| Pneumonia | 1 | 2016 | 196 | 0.110 |
Why?
|
| Cohort Studies | 2 | 2011 | 3106 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2016 | 322 | 0.100 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2008 | 1965 | 0.100 |
Why?
|
| Accidental Falls | 2 | 2011 | 49 | 0.100 |
Why?
|
| Immunosuppressive Agents | 2 | 2009 | 995 | 0.100 |
Why?
|
| Prospective Studies | 2 | 2011 | 4664 | 0.090 |
Why?
|
| Dementia | 1 | 2014 | 218 | 0.090 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 220 | 0.090 |
Why?
|
| Hypotension, Orthostatic | 1 | 2011 | 4 | 0.090 |
Why?
|
| Benzazepines | 1 | 2012 | 65 | 0.090 |
Why?
|
| Combined Modality Therapy | 2 | 2008 | 1739 | 0.090 |
Why?
|
| Angina Pectoris | 2 | 2008 | 29 | 0.090 |
Why?
|
| Time Factors | 3 | 2010 | 5561 | 0.090 |
Why?
|
| Odds Ratio | 2 | 2010 | 713 | 0.080 |
Why?
|
| Comorbidity | 2 | 2011 | 1011 | 0.080 |
Why?
|
| Drug Synergism | 2 | 2001 | 317 | 0.080 |
Why?
|
| Life Expectancy | 1 | 2010 | 91 | 0.080 |
Why?
|
| Cardiovascular Agents | 1 | 2010 | 61 | 0.080 |
Why?
|
| United States | 3 | 2011 | 7764 | 0.080 |
Why?
|
| Cardiac Tamponade | 1 | 2009 | 23 | 0.080 |
Why?
|
| Edema | 1 | 2009 | 73 | 0.080 |
Why?
|
| Logistic Models | 2 | 2011 | 1267 | 0.080 |
Why?
|
| Atrioventricular Block | 1 | 2009 | 27 | 0.080 |
Why?
|
| Vipoma | 1 | 2009 | 5 | 0.070 |
Why?
|
| Vasoactive Intestinal Peptide | 1 | 2009 | 16 | 0.070 |
Why?
|
| California | 1 | 2009 | 161 | 0.070 |
Why?
|
| Diabetes Complications | 1 | 2010 | 175 | 0.070 |
Why?
|
| Health Status Indicators | 1 | 2009 | 104 | 0.070 |
Why?
|
| Treatment Failure | 1 | 2009 | 297 | 0.070 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2008 | 6 | 0.070 |
Why?
|
| Mediastinal Neoplasms | 1 | 2009 | 44 | 0.070 |
Why?
|
| Probability | 1 | 2010 | 364 | 0.070 |
Why?
|
| Echocardiography, Doppler | 1 | 2010 | 193 | 0.070 |
Why?
|
| HIV | 1 | 2009 | 49 | 0.070 |
Why?
|
| Death, Sudden, Cardiac | 1 | 2009 | 61 | 0.070 |
Why?
|
| Metoprolol | 1 | 2008 | 15 | 0.070 |
Why?
|
| Prosthesis Design | 1 | 2009 | 310 | 0.070 |
Why?
|
| Tilt-Table Test | 1 | 2008 | 4 | 0.070 |
Why?
|
| Chylomicron Remnants | 1 | 2008 | 2 | 0.070 |
Why?
|
| Age Factors | 2 | 2010 | 1957 | 0.070 |
Why?
|
| Platelet Activation | 1 | 2008 | 18 | 0.070 |
Why?
|
| Glipizide | 1 | 2008 | 2 | 0.070 |
Why?
|
| Cyclohexanes | 1 | 2008 | 8 | 0.070 |
Why?
|
| Dietary Supplements | 1 | 2009 | 134 | 0.070 |
Why?
|
| Postoperative Hemorrhage | 1 | 2008 | 50 | 0.070 |
Why?
|
| Diagnostic Errors | 1 | 2009 | 158 | 0.070 |
Why?
|
| Fibrosis | 1 | 2009 | 235 | 0.070 |
Why?
|
| Ventricular Premature Complexes | 1 | 2008 | 8 | 0.070 |
Why?
|
| Carbamates | 1 | 2008 | 16 | 0.070 |
Why?
|
| Phenylalanine | 1 | 2008 | 36 | 0.070 |
Why?
|
| Blood Platelets | 1 | 2008 | 154 | 0.070 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2001 | 1267 | 0.070 |
Why?
|
| Drug Resistance | 1 | 2008 | 234 | 0.070 |
Why?
|
| Sulfonylurea Compounds | 1 | 2008 | 68 | 0.070 |
Why?
|
| Hemolysis | 1 | 2007 | 63 | 0.070 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 41 | 0.070 |
Why?
|
| ROC Curve | 1 | 2010 | 797 | 0.070 |
Why?
|
| Acute Disease | 1 | 2009 | 859 | 0.070 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 900 | 0.070 |
Why?
|
| Blood Transfusion | 1 | 2008 | 180 | 0.070 |
Why?
|
| Vascular Diseases | 1 | 2008 | 122 | 0.060 |
Why?
|
| Heart Valve Prosthesis Implantation | 1 | 2009 | 197 | 0.060 |
Why?
|
| Immunoglobulin Fab Fragments | 1 | 2008 | 87 | 0.060 |
Why?
|
| Drug Administration Schedule | 1 | 2008 | 857 | 0.060 |
Why?
|
| Administration, Oral | 1 | 2008 | 686 | 0.060 |
Why?
|
| Pacemaker, Artificial | 1 | 2008 | 105 | 0.060 |
Why?
|
| Exercise Test | 1 | 2008 | 178 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2009 | 325 | 0.060 |
Why?
|
| Piperidines | 1 | 2008 | 171 | 0.060 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 238 | 0.060 |
Why?
|
| Pregnancy Trimester, Third | 1 | 2006 | 71 | 0.060 |
Why?
|
| Patient Readmission | 1 | 2010 | 413 | 0.060 |
Why?
|
| Registries | 1 | 2011 | 985 | 0.060 |
Why?
|
| Catheterization, Peripheral | 1 | 2006 | 64 | 0.060 |
Why?
|
| Th1 Cells | 1 | 2007 | 172 | 0.060 |
Why?
|
| Cyclosporine | 1 | 2006 | 242 | 0.060 |
Why?
|
| Syndrome | 1 | 2006 | 450 | 0.060 |
Why?
|
| Reoperation | 1 | 2008 | 707 | 0.060 |
Why?
|
| Insulin Resistance | 1 | 2008 | 380 | 0.060 |
Why?
|
| Intensive Care Units | 1 | 2009 | 460 | 0.060 |
Why?
|
| Fibrinolytic Agents | 1 | 2007 | 240 | 0.060 |
Why?
|
| Thrombosis | 1 | 2008 | 326 | 0.060 |
Why?
|
| Cross Infection | 1 | 2006 | 159 | 0.060 |
Why?
|
| Interferon-gamma | 1 | 2007 | 462 | 0.060 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2008 | 395 | 0.050 |
Why?
|
| Rats | 2 | 2001 | 4154 | 0.050 |
Why?
|
| Case-Control Studies | 1 | 2008 | 1957 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2008 | 3904 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2008 | 630 | 0.050 |
Why?
|
| Injections, Spinal | 1 | 2003 | 50 | 0.050 |
Why?
|
| Recurrence | 1 | 2006 | 1211 | 0.050 |
Why?
|
| Therapeutic Irrigation | 1 | 2003 | 66 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 1 | 2009 | 725 | 0.050 |
Why?
|
| Heart Transplantation | 1 | 2009 | 811 | 0.050 |
Why?
|
| Clinical Trials as Topic | 1 | 2008 | 1166 | 0.050 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 790 | 0.050 |
Why?
|
| Chi-Square Distribution | 1 | 2003 | 362 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2009 | 2773 | 0.040 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 1425 | 0.040 |
Why?
|
| Heart Ventricles | 1 | 2006 | 810 | 0.040 |
Why?
|
| Biomarkers | 1 | 2008 | 1931 | 0.040 |
Why?
|
| Purinergic P2 Receptor Agonists | 1 | 2000 | 3 | 0.040 |
Why?
|
| Purinergic P2 Receptor Antagonists | 1 | 2000 | 4 | 0.040 |
Why?
|
| Adrenergic alpha-1 Receptor Agonists | 1 | 2000 | 4 | 0.040 |
Why?
|
| Adrenergic alpha-Agonists | 1 | 2001 | 34 | 0.040 |
Why?
|
| Nucleic Acid Synthesis Inhibitors | 1 | 2000 | 17 | 0.040 |
Why?
|
| Culture Techniques | 1 | 2000 | 87 | 0.040 |
Why?
|
| Maleimides | 1 | 2000 | 27 | 0.040 |
Why?
|
| Pain | 2 | 2014 | 426 | 0.040 |
Why?
|
| Signal Transduction | 2 | 2001 | 3581 | 0.040 |
Why?
|
| Receptors, Cell Surface | 1 | 2001 | 297 | 0.040 |
Why?
|
| Protein Kinase C | 1 | 2000 | 265 | 0.040 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2008 | 1230 | 0.040 |
Why?
|
| Pregnancy | 1 | 2006 | 3237 | 0.040 |
Why?
|
| Indoles | 1 | 2000 | 317 | 0.040 |
Why?
|
| Hemodynamics | 1 | 2001 | 775 | 0.030 |
Why?
|
| Enzyme Inhibitors | 1 | 2000 | 655 | 0.030 |
Why?
|
| Animals | 3 | 2001 | 28889 | 0.030 |
Why?
|
| Cells, Cultured | 1 | 2001 | 2929 | 0.030 |
Why?
|
| Paresthesia | 1 | 2014 | 17 | 0.030 |
Why?
|
| Polysomnography | 1 | 2015 | 155 | 0.030 |
Why?
|
| Peripheral Nervous System Diseases | 1 | 2014 | 92 | 0.030 |
Why?
|
| Neurons | 1 | 2001 | 1653 | 0.020 |
Why?
|
| Hepatitis C | 1 | 2014 | 184 | 0.020 |
Why?
|
| Outpatients | 1 | 2011 | 105 | 0.020 |
Why?
|
| Veterans | 1 | 2011 | 100 | 0.020 |
Why?
|
| Hospitals, Veterans | 1 | 2010 | 23 | 0.020 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2010 | 35 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2010 | 393 | 0.020 |
Why?
|
| Indium Radioisotopes | 1 | 2009 | 10 | 0.020 |
Why?
|
| Hypokalemia | 1 | 2009 | 24 | 0.020 |
Why?
|
| Octreotide | 1 | 2009 | 29 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2009 | 206 | 0.020 |
Why?
|
| Irritable Bowel Syndrome | 1 | 2009 | 46 | 0.020 |
Why?
|
| Antineoplastic Agents, Hormonal | 1 | 2009 | 154 | 0.020 |
Why?
|
| Monokines | 1 | 2007 | 3 | 0.020 |
Why?
|
| Arteritis | 1 | 2007 | 9 | 0.020 |
Why?
|
| Interleukin-18 | 1 | 2007 | 29 | 0.020 |
Why?
|
| Lymphokines | 1 | 2007 | 75 | 0.020 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2007 | 126 | 0.020 |
Why?
|
| Interleukin-12 | 1 | 2007 | 116 | 0.020 |
Why?
|
| Brain | 1 | 2015 | 2480 | 0.010 |
Why?
|
| Liver | 1 | 2009 | 1231 | 0.010 |
Why?
|
| Cytokines | 1 | 2007 | 871 | 0.010 |
Why?
|